all-trans retinoic acid (ATRA)

Phase 3Small molecule

Incyte

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Arsenic TrioxideNot yet recruiting

Arsenic TrioxidePhase 3

Not yet recruiting

Timeline

Expected Milestones

Q1 2029

Phase 3Not yet recruiting

Arsenic Trioxide

NCT07296445

Clinical

Trials by Indication[1]

Arsenic Trioxide1 trial

A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)

Not yet recruiting·SSDK Therapeutics, Inc.·Phase 3·NCT07296445·120 enrolled

OIC1 trial

All-trans Retinoic Acid, and Arsenic +/- Idarubicin

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00413166·78 enrolled

Leukemia1 trial

Differentiation Induction in Acute Myelogenous Leukemia

Completed·UUniversity of Bergen·Phase 1/2·NCT00175812·24 enrolled

Acute Promyelocytic Leukemia1 trial

Phase III Trial in Acute Promyelocytic Leukemia Patients

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 3·NCT00482833·276 enrolled

SCLC1 trial

To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00617409·69 enrolled

9 more indications

Lung Cancer1 trial

Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00601796·24 enrolled

Daratumumab1 trial

Daratumumab in Combination With ATRA

Completed·AAmsterdam UMC, location VUmc·Phase 1/2·NCT02751255·60 enrolled

Sclerosing Cholangitis1 trial

Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis

Completed·YYale University·Phase 1·NCT01456468·19 enrolled

Azacytidine1 trial

Phase II 5-Azacytidine Plus VPA Plus ATRA

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00326170·34 enrolled

Acute Myeloid Leukemia1 trial

Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation

Completed·UUniversity of Ulm·Phase 3·NCT01237808·144 enrolled

Multiple Myeloma1 trial

Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT01985477·2 enrolled

Relapsed/Refractory AML1 trial

Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML

Completed·WWashington University School of Medicine·Phase 1·NCT01161550·11 enrolled

Advanced Malignancies1 trial

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Terminated· Incyte logo

Incyte·Phase 1/2·NCT02712905·116 enrolled

Unspecified2 trials

AIDA 2000 Guidelines

Unknown status·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 2·NCT01064570·600 enrolled

"AIDA" Protocol (LAP 0493)

Unknown status·GGruppo Italiano Malattie EMatologiche dell'Adulto·N/A·NCT01064557·1,068 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for all-trans retinoic acid (ATRA). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — all-trans retinoic acid (ATRA) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for all-trans retinoic acid (ATRA). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Incyte company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Incyte